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Breast cancer risk is influenced by rare coding variants in susceptibility genes such as BRCA1 and 477 
many common, mainly non-coding variants. However, much of the genetic contribution to breast 478 
cancer risk remains unknown. We report results from a genome-wide association study (GWAS) of 479 
breast cancer in 122,977 cases and 105,974 controls of European ancestry and 14,068 cases and 480 
13,104 controls of East Asian ancestry
1
. We identified 65 new loci associated with overall breast 481 
cancer at p<5x10
-8
. The majority of credible risk SNPs in the new loci fall in distal regulatory 482 
elements, and by integrating in-silico data to predict target genes in breast cells at each locus, we 483 
demonstrate a strong overlap between candidate target genes and somatic driver genes in breast 484 
tumours. We also find that heritability of breast cancer due to all SNPs in regulatory features was 485 
2-5-fold enriched relative to the genome-wide average, with strong enrichment for particular 486 
transcription factor binding sites. These results provide further insight into genetic susceptibility to 487 
breast cancer and will improve the utility of genetic risk scores for individualized screening and 488 
prevention. 489 
 490 
  491 
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We genotyped 61,282 female breast cancer cases and 45,494 female controls of European ancestry 492 
with the OncoArray
1
. Subjects came from 68 studies collaborating in the Breast Cancer Association 493 
Consortium (BCAC) and Discovery, Biology and Risk of Inherited Variants in Breast Cancer 494 
Consortium (DRIVE) (Supplementary Table 1). Using the 1000 Genomes Project (Phase 3) reference 495 
panel, we imputed genotypes for ~21M variants. After filtering on minor allele frequency 496 
(MAF)>0.5% and imputation quality score>0.3 (see Online Methods), we assessed the association 497 
between breast cancer risk and 11.8M SNPs adjusting for country and ancestry-informative principal 498 
components. We combined these results with results from the iCOGS project (46,785 cases and 499 
42,892 controls)
2
 and 11 other breast cancer GWAS (14,910 cases, 17,588 controls), using a fixed-500 
effect meta-analysis.  501 
 502 
Of 102 loci previously associated with breast cancer in Europeans, 49 showed evidence for 503 
association with overall breast cancer in the OncoArray dataset at P<5x10-8 and 94 at P<0.05. Five 504 
additional loci previously shown to be associated with breast cancer in Asian women also showed 505 
evidence in the European ancestry OncoArray dataset (P<0.01; Supplementary Tables 2-4)3-5. We 506 
also assessed the association with breast cancer in Asians including 7,799 cases and 6,480 controls 507 
from the OncoArray project and 6,269 cases and 6,624 controls from iCOGS. Of the 94 loci previously 508 
identified in Europeans that were polymorphic in Asians, 50 showed evidence of association 509 
(P<0.05). For the remaining 44, none showed a significant difference in the estimated odds ratio 510 
(OR) for overall breast cancer between Europeans and Asians (P>0.01; Supplementary Table 5). The 511 
correlation in effect sizes for all known loci between Europeans and Asians was 0.83, suggesting that 512 
the majority of known susceptibility loci are shared between these populations. 513 
 514 
To search for additional susceptibility loci, we assessed all SNPs excluding those within 500kb of a 515 
known susceptibility SNPs (Figure 1). This identified 5,969 variants in 65 regions that were associated 516 
with overall breast cancer risk at P<5x10-8 (Table 1, Supplementary Tables 6-7). For two loci (lead 517 
SNPs rs58847541 and rs12628403), there was evidence of a second association signal after 518 
adjustment for the primary signal (rs13279803: conditional P=1.6x10-10; rs373038216: P=2.9x10-11; 519 
Supplementary Table 8). Of the 65 new loci, 21 showed a differential association by ER-status 520 
(P<0.05) with all but two (rs6725517 and rs6569648) more strongly associated with ER-positive 521 
disease (Supplementary Tables 9-10). Forty-four loci showed evidence of association for ER-negative 522 
breast cancer (P<0.05). Of the 51 novel loci that were polymorphic in Asians, nine were associated at 523 
P<0.05 and only two showed a difference in the estimated OR between Europeans and Asians 524 
(P<0.01; Supplementary Table 11). 525 
13 
 
To define a set of credible risk variants (CRVs) at the new loci, we first selected variants with P-values 526 
within two orders of magnitude of the most significant SNPs in each region. Across the 65 novel 527 
regions, we identified 2,221 CRVs (Supplementary Table 12), while the previous 77 identified loci 528 
contained 2,232 CRVs (Online methods; Supplementary Table 13). We examined the evidence for 529 
enrichment in these CRVs of 67 genomic features, including histone marks and transcription factor 530 
binding sites (TFBS) in three breast cancer cell lines (Online Methods; Supplementary Tables 14-15; 531 
Extended Data Fig. 1). Thirteen features were significant predictors of CRVs at P<10-4; the strongest 532 
being DNAse I hypersensitivity sites in CTCF silenced MCF7 cells (OR 2.38, P=4.6x10-14). Strong 533 
associations were also observed with binding sites for FOXA1, ESR1, GATA3, E2F1 and TCF7L2. Seven 534 
of the 65 novel loci included only a single CRV (Supplementary Table 6), of which two are non-535 
synonymous. SNP rs16991615 is a missense variant (p.Glu341Lys) in MCM8, involved in genome 536 
replication and associated with age at natural menopause and impaired DNA repair
6. SNP 537 
rs35383942 is a missense variant (p.Arg28Gln) in PHLDA3, encoding a p53-regulated repressor of 538 
AKT
7
.  539 
 540 
We annotated each CRV with publicly available genomic data from breast cells in order to highlight 541 
potentially functional variants, predict target genes and prioritise future experimental validation 542 
(Supplementary Tables 6 and 12 with UCSC browser links). We developed a heuristic scoring system 543 
based on breast-specific genomic data (integrated expression quantitative trait and in silico 544 
prediction of GWAS targets - INQUISIT) to rank the target genes at each locus (Supplementary Table 545 
16). Target genes were predicted by combining risk SNP data with multiple sources of genomic 546 
information, including chromatin interactions (ChIA-PET and Hi-C), computational enhancer-547 
promoter correlations (PreSTIGE, IM-PET, FANTOM5 and Super-enhancers), breast tissue-specific 548 
eQTL results, TF binding (ENCODE ChIP-seq), gene expression (ENCODE RNA-seq) and topologically-549 
associated domain (TAD) boundaries (Online Methods and Supplementary Tables 17-19). Target 550 
gene predictions could be made for 58/65 new and 70/77 previously identified loci. Among 689 551 
protein-coding genes predicted by INQUISIT, we found strong enrichment for established breast 552 
cancer drivers identified through tumour sequencing (20/147 genes, P<10-6)8-11, which increased 553 
with increasing INQUISIT score (P=1.8x10-6). We compared INQUISIT with a) an alternative published 554 
method (DEPICT, which predicts targets based on shared gene functions between potential targets 555 
at other associated loci)
12
 which showed a weaker enrichment of breast cancer driver genes (P=0.06 556 
after adjusting for the nearest gene, P=0.74 after adjusting for INQUIST score, and b) assigning the 557 
association signal to the nearest gene, which showed only a weak enrichment of driver genes after 558 
adjusting for the INQUISIT score (P=0.01; Extended Data Table 1 and Supplementary Table 20). 559 
14 
 
Notably, most of the 689 putative target genes have no reported involvement in breast 560 
tumorigenesis and some may represent additional genes influencing susceptibility to breast cancer. 561 
However, functional assays will be required to confirm any of these candidates as risk genes. 562 
 563 
Having used INQUISIT to predict target genes, we performed pathway gene set enrichment analysis 564 
(GSEA), visually summarized as enrichment maps (Extended Data Fig. 2; Supplementary Tables 21-565 
22)
13
. Several growth or development related pathways were enriched, notably the fibroblast 566 
growth factor, platelet derived growth factor and Wnt signalling pathways
14-16
. Other cancer-related 567 
themes included ERK1/2 cascade, immune-response pathways including interferon signalling, and 568 
cell-cycle pathways. Pathways not found in earlier breast cancer GWAS include nitric oxide 569 
biosynthesis, AP-1 transcription factor and NF-kB (Supplementary Table 23). 570 
 571 
To explore more globally the genomic features contributing to breast cancer risk, we estimated the 572 
proportion of genome-wide SNP heritability attributable to 53 publicly available annotations
17
. We 573 
observed the largest enrichment in heritability (5.2-fold, P=8.5x10-5) for TFBS, followed by a 4-fold 574 
(P=0.0006) enrichment for histone marker H3K4me3 (marking promoters). In contrast, we observed 575 
a significant depletion (0.27, P=0.0007) for repressed regions (Supplementary Table 24). We 576 
conducted cell type-specific enrichment analysis for four histone marks and observed significant 577 
enrichments in several tissue types (Figure 2; Extended Data Figs. 3-7; Supplementary Table 25-26), 578 
including a 6.7-fold enrichment for H3K4me1 in breast myoepithelial tissue (P=7.9x10-5). We 579 
compared the cell type-specific enrichments for overall, ER-positive and ER-negative breast cancer to 580 
the enrichments for 16 other complex traits (Extended Data Figs. 3-7). Breast cancer showed 581 
enrichment for adipose and epithelial cell types (including breast epithelial cells). In contrast, 582 
psychiatric diseases showed enrichment specific to central-nervous-system cell types and 583 
autoimmune disorders showed enrichment for immune cells. 584 
 585 
We selected for further evaluation four loci to represent those predicted to act through proximal 586 
regulation (1p36 and 11p15) and distal regulation (1p34 and 7q22), because they had a relatively 587 
small number of CRVs. The only CRV at 1p36, rs2992756 (P=1.6x10-15), is located 84bp from the 588 
transcription start site of KLHDC7A. Of the 19 CRVs at 11p15 (smallest P=1.4x10-12), five were located 589 
in the proximal promoter of PIDD1, implicated in DNA-damage-induced apoptosis and 590 
tumorigenesis
18
. INQUIST predicted KLHDC7A and PIDD1 to be target genes and they received the 591 
highest score for likelihood of promoter regulation (Supplementary Table 18). Using reporter assays, 592 
we showed that the KLHDC7A promoter construct containing the risk T-allele of rs2992756 has 593 
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significantly lower activity than the reference construct, while the PIDD1 promoter construct 594 
containing the risk haplotype significantly increased PIDD1 promoter activity (Extended Data Fig. 8). 595 
 596 
The 1p34 locus included four CRVs (smallest P=9.1x10-9) that fall within two putative regulatory 597 
elements (PREs) and are predicted by INQUISIT to regulate CITED4 (PREs; Extended Data Fig. 8). 598 
CITED4 encodes a transcriptional coactivator that interacts with CBP/p300 and TFAP2 and can inhibit 599 
hypoxia-activated transcription in cancer cells
19
. Chromatin conformation capture (3C) assays 600 
confirmed that the PREs physically interacted with the CITED4 promoter (Extended Data Fig. 8). 601 
Subsequent reporter assays showed that the PRE1 reference construct reduced CITED4 promoter 602 
activity, whereas the risk T-allele of SNP rs4233486 located in PRE1 negates this effect. 603 
 604 
Finally, the 7q22 risk locus contained six CRVs (smallest P=5.1x10-12) which lie in several PREs 605 
spanning ~40kb of CUX1 intron 1. Chromatin interactions were identified between a PRE1 606 
(containing SNP rs6979850) and CUX1/RASA4 promoters and a PRE2 (containing SNP rs71559437) 607 
and RASA4/PRKRIP1 promoters (Extended Data Fig. 9). Allele-specific 3C in heterozygous MBA-MB-608 
231 cells showed that the risk haplotype was associated with chromatin looping, suggesting that the 609 
protective allele abrogates looping between the PREs and target genes (Extended Data Fig. 9). These 610 
results identify two mechanisms by which CRVs may impact target gene expression: through 611 
transactivation of a specific promoter and by affecting chromatin looping between regulatory 612 
elements and their target genes. These data provide in vitro evidence of target identification and 613 
regulation, however further studies that include genome editing, oncogenic assays and/or animal 614 
models will be required to fully elucidate disease-related gene function.  615 
  616 
We estimate that the newly identified susceptibility loci explain ~4% of the two-fold familial relative 617 
risk (FRR) of breast cancer and that in total, common susceptibility variants identified through GWAS 618 
explain 18% of the FRR. Further, we estimate that variants imputable from the OncoArray, under a 619 
log-additive model (see Online Methods), explain ~41% of the FRR, and thus, the identified 620 
susceptibility SNPs account for ~44% (18%/41%) of the FRR that can be explained by all imputable 621 
SNPs. The identified SNPs will be incorporated into risk prediction models, which can be used to 622 
improve the identification of women at high and low risk of breast cancer: for example, using a 623 
polygenic risk score based on the variants identified to date, women in the highest 1% of the 624 
distribution have a 3.5-fold greater breast cancer risk than the population average. Such risk 625 
prediction can inform targeted early detection and prevention. 626 
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Table 1. Newly identified susceptibility loci for overall breast cancer
1
. 627 
Locus Variant
1
 Chr
2
 Position
3
 Alleles
4
 MAF
5
 
GWAS iCOGS OncoArray 
Combined 
P-value 
Genes
8 
OR (95%CI)
6
P
7
OR (95%CI)
6
P
7
OR (95%CI)
6
P
7
1p36.13 rs2992756 1 18807339 C/T 0.49 1.03(0.99-1.06) 1.4x10
-01
1.05(1.03-1.07) 1.3x10
-05
1.06(1.04-1.08) 1.3x10
-11
1.6x10
-15
KLHDC7A 
1p34.2 rs4233486 1 41380440 T/C 0.36 0.97(0.93-1) 6.6x10
-02
0.95(0.93-0.97) 3.6x10
-05
0.97(0.95-0.98) 2.3x10
-04
9.1x10
-09
-
1p34.2 rs79724016 1 42137311 T/G 0.03 0.85(0.77-0.95) 3.3x10
-03
0.90(0.85-0.95) 1.1x10
-04
0.93(0.88-0.97) 3.3x10
-03
3.5x10
-08 HIVEP3 
1p34.1 rs1707302 1 46600917 G/A 0.34 0.97(0.93-1) 7.2x10
-02
 0.96(0.94-0.98) 3.1x10
-04
 0.96(0.95-0.98) 1.4x10
-04
 3.0x10
-08
 
PIK3R3, 
LOC101929626 
1p32.3 rs140850326 1 50846032 I/D
9
0.49 0.94(0.91-0.98) 1.5x10
-03
0.97(0.95-0.99) 2.3x10
-03
0.97(0.95-0.99) 3.4x10
-04
3.9x10
-08
-
1p22.3 rs17426269 1 88156923 G/A 0.15 1.06(1.01-1.12) 1.1x10
-02
1.05(1.02-1.08) 6.6x10
-04
1.05(1.02-1.07) 1.7x10
-04
1.7x10
-08
-
1p12 rs7529522 1 118230221 T/C 0.23 1.06(1.01-1.12) 1.4x10
-02
1.03(1.01-1.05) 8.7x10
-03
1.06(1.04-1.08) 1.6x10
-08
1.7x10
-10
-
1q22 rs4971059 1 155148781 G/A 0.35 1.07(1.03-1.11) 3.7x10
-04
1.02(1-1.05) 1.4x10
-02
1.05(1.03-1.07) 3.9x10
-08
4.8x10
-11 TRIM46 
1q32.1 rs35383942 1 201437832 C/T 0.06 1.08(0.99-1.17) 7.0x10
-02
1.09(1.04-1.14) 1.9x10
-04
1.12(1.08-1.17) 12x10
-09
3.8x10
-13
PHLDA3 
1q41 rs11117758 1 217220574 G/A 0.21 0.95(0.91-0.99) 2.3x10
-02
0.97(0.95-0.99) 7.8x10
-03
0.95(0.93-0.97) 7.7x10
-07
3.9x10
-09
ESRRG 
2p25.1 rs113577745 2 10135681 C/G 0.1 1.08(1.02-1.14) 8.9x10
-03
1.05(1.02-1.08) 3.7x10
-03
1.08(1.05-1.11) 3.7x10
-07
3.9x10
-10 GRHL1 
2p23.3 rs6725517 2 25129473 A/G 0.41 0.95(0.91-0.98) 1.8x10
-3
0.95(0.93-0.97) 8.5x10
-06
0.96(0.94-0.98) 7.5x10
-06
2.9x10
-12 ADCY3 
2q13 rs71801447 2 111925731 
CTTATGTT
/C 
0.06 1.06(0.98-1.14) 1.6x10
-01
 1.06(1.02-1.11) 2.5x10
-03
 1.09(1.05-1.13) 7.7x10
-06
 3.7x10
-08
 BCL2L11 
2q36.3 rs12479355 2 227226952 A/G 0.21 0.94(0.9-0.98) 2.5x10
-03
0.96(0.94-0.98) 8.8x10
-04
0.96(0.94-0.98) 4.7x10
-04
2.4x10
-08
-
3p13 rs6805189 3 71532113 T/C 0.48 0.96(0.92-0.99) 1.1x10
-02
0.97(0.95-0.99) 9.5x10
-04
0.97(0.95-0.99) 3.3x10
-04
4.6x10
-08
FOXP1 
3p12.1 rs13066793 3 87037543 A/G 0.09 0.91(0.84-0.99) 2.8x10
-02
0.93(0.9-0.96) 1.7x10
-05
0.94(0.91-0.97) 1.5x10
-04
1.0x10
-09 VGLL3 
3p12.1 rs9833888 3 99723580 G/T 0.22 1.06(1.01-1.1) 9.7x10
-03
1.03(1.01-1.06) 5.4x10
-03
1.06(1.04-1.08) 2.6x10
-07
5.2x10
-10 CMSS1, FILIP1L 
3q23 rs34207738 3 141112859 CTT/C 0.41 1.04(1-1.07) 7.0x10
-02
1.05(1.03-1.07) 1.4x10
-06
1.06(1.04-1.08) 1.4x10
-09
3.2x10
-15
ZBTB38 
3q26.31 rs58058861 3 172285237 G/A 0.21 1.05(1.01-1.1) 1.2x10
-02
1.03(1.01-1.05) 1.2x10
-02
1.06(1.04-1.09) 1.6x10
-08
1.9x10
-10
-
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4p14 rs6815814 4 38816338 A/C 0.26 1.05(1-1.09) 2.8x10
-02
1.05(1.03-1.07) 2.2x10
-05
1.06(1.04-1.08) 6.1x10
-08
6.1x10
-13
-
4q21.23 4:84370124 4 84370124 TA/TAA 0.47 1.02(0.99-1.06) 2.1x10
-01
1.05(1.03-1.07) 3.6x10
-06
1.04(1.02-1.05) 1.7x10
-04
2.2x10
-09 HELQ 
4q22.1 rs10022462 4 89243818 C/T 0.44 1.07(1.03-1.1) 3.5x10
-04
1.03(1.01-1.05) 6.3x10
-03
1.04(1.02-1.06) 9.4x10
-06
1.6x10
-09
LOC105369192 
4q28.1 rs77528541 4 126843504 G/T 0.13 0.91(0.86-0.96) 6.3x10
-04
0.95(0.92-0.98) 1.2x10
-03
0.95(0.92-0.97) 4.8x10
-05
1.4x10
-09
-
5p15.33 rs116095464 5 345109 T/C 0.05 1.14(1.05-1.23) 1.5x10
-03
1.1(1.05-1.14) 1.8x10
-05
1.06(1.02-1.1) 2.6x10
-03
3.8x10
-09 AHRR 
5q11.1 rs72749841 5 49641645 T/C 0.16 0.93(0.87-1) 3.7x10
-02
0.93(0.89-0.96) 1.9x10
-04
0.93(0.91-0.96) 8.5x10
-06
7.2x10
-10
-
5q11.1 rs35951924 5 50195093 A/AT 0.32 0.96(0.92-1) 4.4x10
-02
0.95(0.93-0.98) 5.6x10
-05
0.95(0.93-0.97) 4.0x10
-07
1.3x10
-11
-
5q22.1 rs6882649 5 111217786 T/G 0.34 0.94(0.91-0.98) 1.5x10
-03
0.96(0.94-0.98) 2.0x10
-05
0.97(0.95-0.99) 2.7x10
-03
3.7x10
-09
NREP 
5q31.1 rs6596100 5 132407058 C/T 0.25 0.97(0.93-1.01) 1.2x10
-01
0.97(0.95-1) 2.9x10
-02
0.94(0.92-0.96) 5.2x10
-08
7.7x10
-09 HSPA4 
5q35.1 rs4562056 5 169591487 G/T 0.33 1.04(1-1.08) 3.8x10
-02
1.03(1.01-1.06) 1.7x10
-03
1.05(1.03-1.07) 4.1x10
-07
4.7x10
-10
-
6p22.3 rs3819405 6 16399557 C/T 0.33 0.93(0.9-0.97) 6.9x10
-04
0.98(0.96-1) 8.5x10
-02
0.96(0.94-0.97) 2.2x10
-06
1.7x10
-08
ATXN1 
6p22.3 rs2223621 6 20621238 C/T 0.38 1.05(1.02-1.09) 4.2x10
-03
1.04(1.02-1.06) 3.9x10
-05
1.04(1.02-1.06) 1.0x10
-04
3.0x10
-10
CDKAL1 
6p22.2 rs71557345 6 26680698 G/A 0.07 0.92(0.86-0.98) 1.1x10
-02
0.92(0.89-0.96) 3.1x10
-05
0.92(0.88-0.96) 8.4x10
-05
3.9x10
-10
-
6q14.1 rs12207986 6 81094287 A/G 0.47 0.95(0.92-0.98) 3.9x10
-03
0.96(0.94-0.98) 9.6x10
-05
0.97(0.95-0.98) 2.0x10
-04
1.5x10
-09
-
6q23.1 rs6569648 6 130349119 T/C 0.24 0.91(0.88-0.95) 1.1x10
-05
0.97(0.95-0.99) 8.1x10
-03
0.94(0.92-0.96) 4.8x10
-08
3.0x10
-12
L3MBTL3 
7p15.3 rs7971 7 21940960 A/G 0.35 0.97(0.94-1.01) 1.4x10
-01
 0.97(0.95-0.99) 8.8x10
-04
 0.96(0.94-0.98) 1.4x10
-05
 1.9x10
-08
 
DNAH11, 
CDCA7L 
7p15.1 rs17156577 7 28356889 T/C 0.11 1.11(1.04-1.18) 1.5x10
-03
1.06(1.03-1.09) 1.9x10
-04
1.05(1.02-1.08) 3.8x10
-04
4.3x10
-09
CREB5 
7q21.3 rs17268829 7 94113799 T/C 0.28 1.07(1.03-1.11) 2.6x10
-04
1.05(1.02-1.07) 3.6x10
-05
1.05(1.03-1.07) 1.3x10
-06
4.5x10
-13
-
7q22.1 rs71559437 7 101552440 G/A 0.12 0.96(0.91-1.01) 1.0x10
-01
0.92(0.89-0.95) 2.5x10
-06
0.93(0.91-0.96) 9.1x10
-07
5.1x10
-12
CUX1 
8q22.3 rs514192 8 102478959 T/A 0.32 1.06(1.02-1.1) 1.3x10
-03
1.03(1-1.05) 1.6x10
-02
1.05(1.03-1.07) 3.7x10
-06
5.6x10
-09
-
8q23.1 rs12546444 8 106358620 A/T 0.1 0.94(0.88-0.99) 3.1x10
-02
0.93(0.89-0.96) 3.1x10
-05
0.93(0.91-0.96) 5.8x10
-06
7.5x10
-11
ZFPM3 
8q24.13 rs58847541 8 124610166 G/A 0.15 1.08(1.03-1.13) 1.7x10
-03
1.05(1.02-1.08) 7.8x10
-04
1.08(1.05-1.1) 7.3x10
-09
5.5x10
-13
-
9q33.1 rs1895062 9 119313486 A/G 0.41 0.97(0.94-1) 7.7x10
-02
0.97(0.95-0.99) 6.4x10
-04
0.94(0.92-0.95) 6.9x10
-13
1.1x10
-14
ASTN2 
9q33.3 rs10760444 9 129396434 A/G 0.43 1.08(1.04-1.11) 3.2x10
-05
1.03(1.01-1.05) 4.9x10
-03
1.03(1.02-1.05) 2.8x10
-04
9.1x10
-09
LMX1B 
9q34.2 rs8176636 9 136151579 I/D
10
0.2 1.05(1-1.1) 5.4x10
-02
1.06(1.03-1.09) 2.5x10
-06
1.03(1.01-1.06) 3.2x10
-03
1.4x10
-08 ABO 
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10p14 rs67958007 10 9088113 TG/T 0.12 1.06(1-1.12) 3.8x10
-02
1.04(1.01-1.07) 1.9x10
-02
1.09(1.06-1.12) 1.8x10
-09
1.7x10
-10
-
10q23.33 rs140936696 10 95292187 C/CAA 0.18 1.07(1.02-1.12) 6.1x10
-03
1.05(1.02-1.08) 5.0x10
-04
1.04(1.02-1.07) 7.4x10
-04
4.2x10
-08
-
11p15 rs6597981 11 803017 G/A 0.48 0.96(0.93-1) 3.3x10
-02
0.96(0.94-0.97) 5.0x10
-06
0.96(0.94-0.97) 5.7x10
-07
1.4x10
-12
PIDD1 
12q21.31 rs202049448 12 85009437 T/C 0.34 0.96(0.92-0.99) 2.2x10
-02
0.98(0.96-1) 6.0x10
-02
0.95(0.93-0.97) 2.5x10
-07
2.7x10
-08
-
12q24.31 rs206966 12 120832146 C/T 0.16 1.04(0.99-1.1) 1.0x10
-01
1.06(1.03-1.09) 1.3x10
-04
1.05(1.02-1.07) 2.7x10
-04
3.8x10
-08 -
14q32.33 rs10623258 14 105212261 C/CTT 0.45 1.06(1.01-1.1) 9.8x10
-03
1.03(1.01-1.05) 3.7x10
-03
1.04(1.02-1.06) 2.7x10
-05
2.3x10
-08 ADSSL1 
16q12.2 rs28539243 16 54682064 G/A 0.49 1.05(1.01-1.09) 1.2x10
-02
1.05(1.03-1.07) 1.3x10
-06
1.05(1.03-1.07) 3.6x10
-08
9.1x10
-15
-
16q13 rs2432539 16 56420987 G/A 0.4 1.05(1.02-1.09) 4.8x10
-03
1.03(1.01-1.05) 1.5x10
-03
1.03(1.02-1.05) 3.1x10
-04
4.0x10
-08
AMFR 
16q24.2 rs4496150 16 87085237 C/A 0.25 0.96(0.92-1) 6.9x10
-02
0.96(0.94-0.98) 3.5x10
-04
0.96(0.94-0.98) 3.4x10
-05
8.1x10
-09
-
17q21.2 rs72826962 17 40836389 C/T 0.01 0.99(0.81-1.2) 8.9x10
-01
1.23(1.12-1.35) 2.6x10
-05
1.2(1.11-1.3) 5.1x10
-06
4.6x10
-09
CNTNAP1 
17q21.31 rs2532263 17 44252468 G/A 0.19 0.92(0.88-0.96) 4.1x10
-04
0.94(0.92-0.97) 1.0x10
-05
0.95(0.93-0.97) 4.7x10
-06
6.9x10
-13
KANSL1 
18q12.1 rs117618124 18 29977689 T/C 0.05 0.86(0.79-0.94) 6.5x10
-04
0.93(0.88-0.97) 2.8x10
-03
0.89(0.85-0.92) 4.5x10
-08
5.5x10
-12
GAREM1 
19p13.13 rs78269692 19 13158277 T/C 0.05 1.08(1-1.17) 5.5x10
-02
1.12(1.06-1.19) 4.8x10
-05
1.09(1.04-1.13) 3.9x10
-05
1.9x10
-09 NFIX1 
19p13.12 rs2594714 19 13954571 G/A 0.23 0.94(0.9-0.98) 1.7x10
-03
0.95(0.93-0.97) 1.6x10
-05
0.97(0.95-0.99) 6.7x10
-03
1.1x10
-08
-
19p13.11 rs2965183 19 19545696 G/A 0.35 1.05(1.01-1.09) 6.2x10
-03
 1.05(1.03-1.07) 6.4x10
-06
 1.04(1.02-1.06) 9.6x10
-06
 6.3x10
-12
 
GATAD2A, 
MIR640 
19q13.22 rs71338792 19 46183031 A/AT 0.23 1.04(1-1.09) 6.5x10
-02
1.05(1.02-1.08) 6.6x10
-04
1.05(1.03-1.07) 8.1x10
-06
3.5x10
-09
GIPR 
20p12.3 rs16991615 20 5948227 G/A 0.06 1.09(1.02-1.17) 1.8x10
-02
1.05(1.01-1.09) 1.5x10
-02
1.1(1.06-1.14) 1.4x10
-07
1.9x10
-09
MCM8 
20q13.13 rs6122906 20 48945911 A/G 0.18 1.08(1.03-1.13) 6.3x10
-04
1.05(1.02-1.07) 3.8x10
-04
1.05(1.03-1.07) 2.9x10
-05
2.5x10
-10
-
22q13.1 rs738321 22 38568833 C/G 0.38 0.94(0.91-0.97) 5.1x10
-04
0.96(0.94-0.98) 1.7x10
-04
0.95(0.93-0.97) 2.7x10
-08
1.0x10
-13
PLA2G6 
22q13.2 rs73161324 22 42038786 C/T 0.06 1.14(1.05-1.25) 2.7x10
-03
1.11(1.06-1.16) 1.4x10
-06
1.06(1.02-1.09) 3.8x10
-03
2.0x10
-09
XRCC6 
22q13.31 rs28512361 22 46283297 G/A 0.11 1.06(0.99-1.14) 8.4x10
-02
1.08(1.04-1.13) 2.0x10
-05
1.05(1.02-1.08) 5.7x10
-04
2.3x10
-08
-
 628 
1
 The most significant variant at each locus is shown. 629 
2 
Chromosome 630 
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3
 Build 37 position 631 
4
 Major/minor allele (forward strand) 632 
5
 Minor allele frequency in controls in OncoArray dataset 633 
6
 Per-allele odds ratio (95% confidence limits) 634 
7
 P-value (see Online Methods) 635 
8
 Genes within 2kb 636 
9
 21 base-pair deletion 637 
10
 36 base-pair deletion 638 
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Figure Legends 644 
Figure 1. (a) Manhattan plot showing log10P-values for SNP associations with overall breast cancer 645 
(b) Manhattan plot after excluding previously identified associated regions. The red line denotes 646 
genome-wide significance (P<5x10-8); the blue line denotes P<10-5. 647 
  648 
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Online Methods 695 
Details of the studies and genotype calling and quality control (QC) for the iCOGS and eleven other 696 
GWAS are described elsewhere
2,20
. Seventy-eight studies participated in the breast cancer 697 
component of the OncoArray, of which 67 studies contributed European ancestry data and 12 698 
contributed Asian ancestry data (one study, NBCS, was excluded as there were no controls from 699 
Norway) (Supplementary Table 1). The majority of studies were population-based case-control 700 
studies, or case-control studies nested within population-based cohorts, but a subset of studies 701 
oversampled cases with a family history of the disease. All studies provided core data on disease 702 
status and age at diagnosis/observation, and the majority provided additional data on clinico-703 
pathological factors and lifestyle factors, which have been curated and incorporated into the BCAC 704 
database (version 6). All participating studies were approved by their appropriate ethics review 705 
board and all subjects provided informed consent.  706 
OncoArray SNP Selection 707 
Approximately 50% of the SNPs for the OncoArray were selected as a GWAS backbone (Illumina 708 
HumanCore), which aimed to provide high coverage for the majority of common variants through 709 
imputation. The remaining SNPs were selected from lists supplied by each of six disease-based 710 
consortia, together with a seventh list of SNPs of interest to multiple disease-focused groups. 711 
Approximately 72k SNPs were selected specifically for their relevance to breast cancer. These 712 
included: (a) SNPs showing evidence of association from previous genotype data, based on a 713 
combined analysis of eleven existing GWAS together the data from the iCOGS experiment; (b) SNPs 714 
showing evidence of association with ER-negative disease (through a combined analysis with the 715 
CIMBA consortium), triple negative disease, breast cancer diagnosed before age 40 years, high grade 716 
disease, node positive disease or ductal carcinoma-in-situ; (c) SNPs potentially associated with 717 
breast cancer survival; (d) SNPs selected for fine-mapping of 55 regions showing evidence of breast 718 
cancer association at genome-wide significance; (e) rare variants showing evidence of association  719 
through exome sequencing in multiple case families, whole-genome sequencing in high-risk cases 720 
(DRIVE), or analysis of the ExomeChip (BCAC); (f) specific follow-up of regions of interest from breast 721 
cancer GWAS in Asian, Latina and African/African-American women; (g) SNPs associated with breast 722 
density, selected from GWAS conducted by the MODE consortium; (h) breast tissue-specific eQTLs (i) 723 
lists of functional candidates from >30 groups. Lists were merged with lists from the other consortia 724 
as described elsewhere
1
.  725 
OncoArray Calling and QC 726 
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Of the 568,712 variants selected for genotyping, 533,631 were successfully manufactured on the 727 
array (including 778 duplicate probes). Genotyping for the breast cancer component of the 728 
OncoArray, which included 152,492 samples, was conducted at six sites. Details of the genotyping 729 
calling for the OncoArray are described in more detail elsewhere
1
. Briefly, we developed a single 730 
calling pipeline that was applied to more than 500,000 samples. An initial cluster file was generated 731 
using data from 56,284 samples, selected to cover all the major genotyping centres and ethnicities, 732 
using the Gentrain2 algorithm. Variants likely to have problematic clusters were selected for manual 733 
inspection using the following criteria: call rate below 99%, variants with minor allele frequency 734 
(MAF)<0.001, poor Illumina intensity and clustering metrics, or deviation from the expected 735 
frequency as observed in the 1000 Genomes Project. This resulted in manual adjustment of the 736 
cluster file for 3,964 variants, and the exclusion of 16,526 variants. The final cluster file was then 737 
applied to the full dataset. 738 
We excluded probable duplicates and close relatives within each study, and probable duplicates 739 
across studies. We excluded samples with a call rate <95% or samples with extreme heterozygosity 740 
(4.89 SD from the mean for the ethnicity). Ancestry was computed using a principal component 741 
analysis, applied to the full OncoArray dataset, using 2318 informative markers on a subset of 742 
~47,000 samples. The analysis presented here was restricted to women of European ancestry, 743 
defined as individuals with an estimated proportion of European ancestry >0.8, and women of East 744 
Asian ancestry (estimated proportion of Asian ancestry >0.4), with reference to the HapMap (v2) 745 
populations, based on the first two principal components. After quality control exclusions and 746 
removing overlaps with the previous iCOGS and GWAS genotyping used in the analysis, the final 747 
dataset comprised data from 61,282 cases and 45,494 of European ancestry 7,799 cases and 6,480 748 
controls of Asian ancestry. 749 
We excluded SNPs with a call rate <95% in any consortium, SNPs not in Hardy-Weinberg equilibrium 750 
(P<10-7 in controls or P <10-12 in cases) and SNPs with concordance <98% among 5,280 duplicate 751 
sample pairs. For the imputation, we additionally excluded SNPs with a MAF<1% and a call rate <98% 752 
in any consortium, SNPs that could not be linked to the 1000 Genomes Project reference or differed 753 
significantly in frequency from the 1000 Genomes Project dataset (using the criterion 754 ሺ௣భି௣బሻమ൫ሺ௣భା௣బሻሺଶି௣భି௣బሻ൯ ൐ 	?Ǥ	?	?	?, where p0 and p1 are the MAFs in the 1000 Genomes Project and 755 
OncoArray European datasets, respectively). A further 1,128 SNPs where the cluster plot was judged 756 
to be not ideal on visual inspection were excluded. Of the 533,631 SNPs that were manufactured on 757 
the array, 494,763 SNPs passed the initial QC and 469,364 SNPs were used in the imputation. 758 
Genotype Imputation 759 
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All samples were imputed using the October 2014 (version 3) release of the 1000 Genomes Project 760 
dataset as the reference panel and number of sampled haplotypes per individual (Nhap)=800. The 761 
iCOGS, OncoArray and nine of the GWAS datasets were imputed using a two-stage imputation 762 
approach, using SHAPEIT2 for phasing and IMPUTEv2 for imputation
21,22
. The imputation was 763 
performed in 5Mb non-overlapping intervals. The subjects were split into subsets of ~10,000 764 
samples; where possible subjects from the same study were included in the same subset. The BPC3 765 
and EBCG studies were imputed separately using MACH and Minimac
23,24
. 99.6% of SNPs with 766 
frequency >1% were imputable with r
2
>0.3 in the OncoArray dataset and 99.1% in the iCOGS 767 
dataset. We generated estimated genotypes for all SNPs that were polymorphic (MAF>0.1%) in 768 
either European or Asian samples (~21M SNPs). For the current analysis, however, we restricted to 769 
SNPs with MAF>0.5% in the European OncoArray dataset (11.8M SNPs). One-step imputation 770 
(without pre-phasing) was performed, on the iCOGS and OncoArray datasets, as a quality control 771 
step for those associated loci where the imputation quality score was <0.9. Imputation quality for 772 
the lead variants, as assessed by the IMPUTE2 quality score in the OncoArray dataset, was >0.80 for 773 
all but one locus (Supplementary Table 27) rs72749841, quality score=0.65).  774 
 775 
Principal Components Analysis 776 
To adjust for potential (intra-continental) population stratification in the OncoArray dataset, 777 
principal components analysis was performed using data from 33,661 uncorrelated SNPs (which 778 
included 2,318 SNPs specifically selected on informativeness for determining continental ancestry) 779 
with a MAF of at least 0.05 and maximum correlation of 0.1 in the OncoArray dataset, using 780 
purpose-written software (http://ccge.medschl.cam.ac.uk/software/pccalc). For the main analyses, 781 
we used the first ten principal components, as additional components did not further reduce 782 
inflation in the test statistics. We used nine principal components for the iCOGS and up to ten 783 
principal components for the other GWAS, where this was found to reduce inflation. 784 
Statistical Analyses 785 
Per-allele ORs and standard errors were generated for the OncoArray, iCOGS and each GWAS, 786 
adjusting for principal components using logistic regression. The OncoArray and iCOGS analyses 787 
were additionally adjusted for country and study, respectively. For the OncoArray analysis, we 788 
adjusted for country and 10 principal components. Adjustment for country rather than study was 789 
used to improve power since some studies had no few or no controls. We evaluated the adequacy of 790 
this approach by comparing the inflation in the test statistic with that obtained in corresponding 791 
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analysis in which we adjusted for study  the inflation was very similar (ʄ=1.15 vs. 1.17, based on the 792 
backbone SNPs, equivalent to ʄ1000=1.003, for a study of 1,000 cases and 1,000 controls, in both 793 
cases). As an additional sensitivity analysis, we computed the effect sizes for the 65 novel loci 794 
adjusting for study  the effect sizes were essentially identical to those presented. Estimates were 795 
derived using ProbAbel for the BPC3 and EBCG studies
25
, SNPTEST for the remaining GWAS and 796 
purpose written software for the iCOGS and OncoArray datasets. OR estimates and standard errors 797 
were combined in a fixed effects inverse variance meta-analysis using METAL
26
, adjusting the GWAS 798 
(but not iCOGS or OncoArray) results for genomic control as described previously
2
. For the GWAS, 799 
results were included in the analysis for all SNPs with MAF>0.01 and imputation r
2
>0.3. For iCOGS 800 
and OncoArray we included all SNPs with r
2
>=0.3 and MAF>0.005 (11.8M SNPs in total). We viewed 801 
the primary tests of association as those based on all the meta-analysis over all stages, as this has 802 
been shown to be powerful than tests based on a test-replication approach
27
. Eight sets of variants 803 
were associated with breast cancer at P<5x10-8 but were close to previous susceptibility regions, and 804 
these became non-significant after adjustment for the previously identified lead variant. Two SNPs 805 
on 22q13.2, rs141447235 and rs73161324, were both associated with overall breast cancer but, 806 
despite lying >500kb apart, were strongly correlated with each other (r
2
=0.50) and hence were 807 
considered as a single novel signal.  808 
 809 
For SNPs showing evidence of association, we additionally computed genotype-specific ORs for the 810 
iCOGS and OncoArray dataset, and per-allele ORs for ER-negative and ER-positive disease. 811 
Departures from a log-additive model were evaluated using a one degree of freedom likelihood ratio 812 
test, comparing the log-additive model (genotypes parametrised as the number of rare alleles 813 
carried) with the general model estimating ORs for each genotype. The genotype-specific risks for all 814 
variants were consistent with a log-additive model (P>0.01; Supplementary Table 28). Tests for 815 
differences in the OR by ER-status were derived using case-only analyses, in which estimates were 816 
derived by logistic regression separately in the iCOGS and OncoArray datasets, adjusted as before, 817 
and then combined in a fixed-effects meta-analysis. These analyses were performed in R
28
. 818 
We assessed heterogeneity in the OR estimates among studies within each of the OncoArray, iCOGS 819 
and GWAS components, and between the (combined) estimates for the three components, using 820 
both the I
2
 statistic and the P-value for Cochrans Q statistic (Supplementary Table 27). There was no 821 
evidence of heterogeneity among studies in the ORs for any of the loci in the OncoArray, but three 822 
loci showed some evidence of heterogeneity in the ORs among the GWAS, iCOGS and OncoArray 823 
datasets.  824 
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To determine whether there were multiple independent signals in a given region, we performed 825 
multiple logistic regression analysis using SNPs within 500kb of each lead SNP, adjusting for the lead 826 
SNP. We used the genotypes derived by one-step imputation, performed the analyses separately in 827 
the iCOGS and Oncoarray datasets and combined the results (adjusted effect sizes and standard 828 
errors) using a fixed effects meta-analysis. For one of the two loci for which there was an additional 829 
signal significant at P<5x10-8, the lead SNP from the one-step imputation differed from the lead SNP 830 
in the overall analysis, but was strongly correlated with it (Supplementary Table 8). 831 
 832 
Definition of Known Hits 833 
We attempted to identify all associations previously reported from genome-wide or candidate 834 
analysis at a significance level P<5x10-8 for overall breast cancer, ER-negative or ER-positive breast 835 
cancer, in BRCA1 or BRCA2 carriers, or in meta-analyses of these categories. Where multiple studies 836 
reported associations in the same region, we used the first reported association unless later studies 837 
identified a variant that was clearly more strongly associated. We only included one SNP per 500kb 838 
interval, unless joint analysis provided clear evidence (P<5x10-8) of more than one independent 839 
signal. For the analysis of credible risk variants (CRVs), we restricted attention to regions where the 840 
most significant signal had a P-value<10-7 in Europeans (77 regions). To avoid complications with 841 
defining CRVs for secondary signals, we considered only the primary signal and defined CRVs as 842 
those whose P-value was within two orders of magnitude of the most significant P-value. 843 
In-Silico Analysis of CRVs 844 
We combined multiple sources of in silico functional annotation from public databases to help 845 
identify potential functional SNPs and target genes. To investigate functional elements enriched 846 
across the region encompassing the strongest CRVs, we analysed chromatin biofeatures data from 847 
the Encyclopedia of DNA Elements (ENCODE) Project
29
, Roadmap Epigenomics Projects
30
 and other 848 
data obtained through the National Center for Biotechnology Information (NCBI) Gene Expression 849 
Omnibus (GEO) namely: Chromatin State Segmentation by Hidden Markov Models (chromHMM), 850 
DNase I hypersensitive and histone modifications of epigenetic markers H3K4, H3K9, and H3K27 in 851 
Human Mammary Epithelial (HMEC) and myoepithelial (MYO) cells, T47D and MCF7 breast cancer 852 
cells and TF ChIP-seq in a range of breast cell lines (Supplementary Table 12). 853 
Association of Genomic Features with CRVs 854 
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We first defined credible candidate variants as those located within 500kb of the most significant 855 
SNP in each region, and with P-values within two orders of magnitude of the most significant SNPs. 856 
This is approximately equivalent to flagging variants whose posterior probability of causality is within 857 
two orders of magnitude of that of the most significant SNP
31,32
. We then selected 800 random 1Mb 858 
control regions separated by at least 1Mb from each other and from the intervals defined by the 859 
associated SNPs. The association with each feature was then evaluated using logistic regression, with 860 
being a CRV as the outcome, and adjusting for the dependence due to linkage disequilibrium using 861 
robust variance estimation, clustering on region, using the R package multiwayvcov. 862 
eQTL analyses 863 
Expression QTL analyses were performed using data from The Cancer Genome Atlas (TCGA) and 864 
Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) projects
9,33. The TCGA 865 
eQTL analysis was based on 458 breast tumours that had matched gene expression, copy number, 866 
and methylation profiles together with the corresponding germline genotypes available. All 458 867 
individuals were of European ancestry as ascertained using the genotype data and the Local 868 
Ancestry in adMixed Populations (LAMP) software package (LAMP estimate cut-off >95% 869 
European)
34
. Germline genotypes were imputed into the 1000 Genomes Project reference panel 870 
(October 2014 release) using IMPUTE2
23,35
. Gene expression had been measured on the Illumina 871 
HiSeq 2000 RNA-Seq platform (gene-level RSEM normalized counts
36
), copy number estimates were 872 
derived from the Affymetrix SNP 6.0 (somatic copy number alteration minus germline copy number 873 
variation called using the GISTIC2 algorithm
37
), and methylation beta values measured on the 874 
Illumina Infinium HumanMethylation450. Expression QTL analysis focused on all variants within 500 875 
kb of the most significantly associated risk SNP in 142 genomic regions (each 2-Mb wide) containing 876 
at least one previously identified or new overall breast cancer risk locus confirmed at genome-wide 877 
significance in the current meta-analysis. Each variant was evaluated for its association with the 878 
expression of every gene within 2 Mb that had been profiled for each of the three data types. The 879 
effects of tumour copy number and methylation on gene expression were first regressed out using a 880 
method described previously
38
. eQTL analysis was performed by linear regression, with residual gene 881 
expression as outcome, germline SNP genotype dosage as the covariate of interest and ESR1 882 
expression and age as additional covariates, using the R package Matrix eQTL
39
. 883 
The METABRIC eQTL analysis was based on 138 normal breast tissue samples resected from breast 884 
cancer patients of European ancestry. Germline genotyping for the METABRIC study was also done 885 
on the Affymetrix SNP 6.0 array, and gene expression in the METABRIC study was measured using 886 
the Illumina HT12 microarray platform (probe-level estimates). No adjustment was implemented for 887 
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somatic copy number and methylation status since we were evaluating eQTLs in normal breast 888 
tissue. All other steps were identical to the TCGA eQTL analysis described above. 889 
 890 
INQUISIT  891 
We developed a computational pipeline, integrated expression quantitative trait and in silico 892 
prediction of GWAS targets (INQUISIT), to interrogate publically available data for the prioritisation 893 
of candidate target genes.  894 
 895 
Data used for INQUISIT: Chromatin interaction data from ENCODE ChIA-PET analysis in MCF-7 cells 896 
for RNApolII, ERalpha, and CTCF factors were downloaded using UCSC Table Browser
40
. Hi-C data 897 
derived from HMECs were obtained from Rao et al.41, using interaction loops as defined in the 898 
publication. Data were reformatted to facilitate intersection of query SNPs using BEDTools 899 
intersect
42
. For all interactions, termini were intersected with promoters using GENCODE v19
43
 900 
Basic gene annotations, where we defined promoters as -1.0 kb - +0.1 kb surrounding a transcription 901 
start site.  902 
 903 
Enhancer-target gene predictions by several computational algorithms were collected. Each of these 904 
datasets assigns genes to enhancers. We used all MCF-7 and HMEC enhancer predictions (low and 905 
high stringency) made by PreSTIGE
44
, IM-PET enhancer-gene predictions in MCF-7, HMEC and 906 
HCC1954 cell lines
45
. Enhancer-transcription start site (E-TSS) links were identified from the 907 
FANTOM5 Consortium were identified
46
, and enhancers detected in mammary epithelial cells were 908 
intersected with E-TSS links. We also collected typical and super-enhancers in MCF-7, HMEC and 909 
HCC1954 cells defined by Hnisz et al.47. 910 
 911 
TF ChIP-seq peak data for ESR1, FOXA1, GATA3, TCF7L2 and E2F1 from MCF-7, T47D and MCF-10A 912 
cells were downloaded in narrowPeak format from ENCODE. H3K4me3 and H3K9ac (characteristic of 913 
promoters) histone modification ChIP-seq peak data for all breast cells were obtained from ENCODE 914 
and Roadmap Epigenomics Project. ChromHMM data for breast cell samples (HMEC and 915 
myoepithelial: E027, E028 and E119) were downloaded from Roadmap Epigenomics.  916 
 917 
Expression QTL analyses were conducted as described above. In the interpretation of the eQTL 918 
results for INQUISIT (and in general) we focused on the overlap between the CRVs (risk signal) and 919 
the top eQTL variants for a given gene (eQTL signal). If the eQTL P-value for a CRV was the same as, 920 
or within 1/100
th
 of the eQTL P-value of the SNP most significantly associated with expression of a 921 
29 
 
particular gene, that gene and the corresponding CRV were assigned a point for being an eQTL in 922 
INQUISIT. 923 
 924 
Topologically-associated domain (TAD) boundaries were derived from Hi-C data
41
. Genomic intervals 925 
corresponding to contact domains from eight human cell types were merged using BEDTools 926 
merge resulting in annotation of regions most likely to encompass TAD units. Inter-TAD 927 
boundaries were identified using BEDTools complement.  928 
 929 
Gene level RNA-seq expression data generated under multiple experimental conditions in MCF-7 and 930 
normal mammary epithelial cells were downloaded from ENCODE. The FPKM (Fragments Per 931 
Kilobase of exon per Million fragments Mapped) values for each gene were extracted using the 932 
metagene R package
48
 and averaged across all experiments to give an approximation of expression 933 
in breast cells. Accession numbers are given in Supplementary Table 29. 934 
 935 
INQUISIT pipeline 936 
Candidate target genes were evaluated by assessing each CRVs potential impact on regulatory or 937 
coding features. Scores categorised by 1) distal gene regulation, 2) proximal gene regulation, or 3) 938 
impact on protein coding were calculated using the following criteria (see also Supplementary Table 939 
16).  940 
 941 
Genomic annotation data for target gene predictions (chromatin interaction and computational 942 
enhancer-promoter assignment), ChIP-seq, histone modification, and chromHMM were curated into 943 
a BED formatted database. We intersected the chromosomal positions of CRVs with each category of 944 
genomic annotation data using BEDTools intersect (minimum 1 bp overlap), resulting in 945 
annotation of SNP-gene pairs with presence or absence of multiple classes of genomic data. Each 946 
gene was scored using a custom R script on the basis of the following criteria: 947 
- For distally regulated genes, a candidate gene was given 2 points if a CRV fell in an element that 948 
revealed long range ChIA-PET or Hi-C interactions with that genes promoter. One point was 949 
added to a gene's score in the case of enhancers predicted by computational methods to target 950 
that gene (in addition to experimental interactions if also observed). If the distal elements 951 
harbouring SNPs also overlapped enriched cistromic TF (ESR1, FOXA1, GATA3, TCF7L2, E2F1) 952 
ChIP-seq peaks, an additional point was given when one SNP-Enhancer-ChIP-seq peak 953 
intersection occurred, but two points when there were multiple TF binding sites overlapping SNPs 954 
in distinct interactions or enhancers (see Supplementary Table 16 for details). One point was 955 
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given to significant eSNP-eGENE pairs. Predicted distal target genes which were among the list of 956 
breast cancer driver genes were up-weighted with a further point (except for the analysis of 957 
driver gene enrichment). Information regarding TAD boundaries was used to down-weight genes: 958 
genes which were separated from CRVs by a TAD boundary were down-weighted by multiplying 959 
their scores by 0.05. Scores for genes exhibiting no expression in MCF7 or HMEC (mean FPKM = 960 
0) were multiplied by 0.1. This resulted in scores for each candidate target gene ranging from 0 to 961 
8. 962 
- Variants were treated as potentially affecting proximal promoter regulation if they resided 963 
between -1.0 and +0.1 kb surrounding a transcription start site. Additional points was awarded to 964 
genes when variants overlapped promoter H3K4me3 or H3K9ac histone modification peaks, 965 
intersected with ESR1, FOXA1, GATA3, TCF7L2 or E2F1 TF binding sites, were significant eSNP-966 
eGENE pairs, and if the gene was annotated as a breast cancer driver gene. Gene scores were 967 
down-weighted (by a factor of 0.1) if they lacked expression in MCF-7 or HMEC samples. 968 
Resultant scores ranged from 0 to 5. 969 
- Intragenic variants were evaluated for their potential to impact protein function using a range of 970 
in silico prediction tools (CADD
49
, FATHMM
50
, LRT
51
, MutationAssessor
52
, Mutation Taster 2
53
, 971 
PolyPhen-2
54
, PROVEAN
55
 and SIFT
56
 for missense variants; Human Splicing Finder
57
 and 972 
MaxEntScan
58
 for splice variants). We scored genes with missense and nonsense variants 973 
predicted to be functionally deleterious, and points for genes harbouring variants predicted to 974 
alter splicing. Genes could therefore carry SNPs which affect coding and splicing and receive 975 
increased scores. Additional points were given to genes which were breast cancer driver genes. 976 
We multiplied scores by 0.1 when genes showed a lack of expression in breast cells. Possible 977 
coding scores ranged from 0-4. 978 
 979 
Enrichment of Somatic Breast Cancer Driver Genes in INQUISIT Target Gene Predictions 980 
We listed 147 unique protein coding driver genes for breast cancer identified from four recent 981 
tumour genome and exome sequencing studies (considering ZNF703 and FGFR1 as independent 982 
genes; Supplementary Table 30)
8-11
. First, we examined overlap between this list of 147 genes and 983 
the total set of unique target genes predicted by INQUISIT (n = 689) by one or more of the three 984 
regulatory mechanisms (distal, promoter, and coding). The significance of this overlap was assessed 985 
by randomly drawing (without replacement) 689 genes from the set of all protein coding genes 986 
(GENCODE release 19, n = 20,243) one million times and calculating the probability of observing the 987 
same (or stronger) overlap with the list of 147 drivers. Second, we hypothesised that this enrichment 988 
would be stronger with progressively higher INQUISIT scores. We categorised all 20,243 protein 989 
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coding genes into four levels based on their INQUIST scores (level 1: coding score 2, promoter score 990 
3-4, distal score >4; level 2: coding 1, promoter 1-2, distal 1-4; level 3: any score >0 but <1; level 4: 991 
score 0 i.e. not a predicted target). The gene nearest to a risk locus is frequently assigned as a 992 
candidate target gene in GWAS in the absence of additional functional analysis
59
. We observed that 993 
seven of the 147 drivers were among the genes nearest to a previously or newly identified breast 994 
cancer risk locus. Therefore, we used logistic regression, including data for all target genes predicted 995 
by INQUISIT, with driver status as outcome, and evaluated INQUISIT score level and nearest gene 996 
status as potential predictors of driver status (Supplementary Table 20).  997 
 998 
Lead SNPs at 142 breast cancer risk associated loci were used as input into DEPICT which was then 999 
run using the default settings
12
. We examined the relative performance of INQUISIT and DEPICT in 1000 
predicting driver gene status using logistic regression models as above (Supplementary Table 20), 1001 
adding DEPICT prediction as a covariate.  1002 
Chromatin Conformation Capture (3C)  1003 
MCF7 (ATCC #HTB22) and MDA-MB-231 (ATCC #HTB26) breast cancer cell lines were grown in RPMI 1004 
medium with 10% FCS and antibiotics. Bre-80 normal breast epithelial cells (provided as a gift from 1005 
Roger Reddel, CMRI, Sydney) were grown in DMEM/F12 medium with 5% horse serum (HS), 10 1006 
µg/ml insulin, 0.5 µg/ml hydrocortisone, 20 ng/ml epidermal growth factor, 100 ng/ml cholera toxin 1007 
and antibiotics. Cell lines were maintained under standard conditions, routinely tested for 1008 
Mycoplasma and short tandem repeat (STR) profiled to confirm cell line identity. 3C libraries were 1009 
generated using EcoRI as described previously60. 3C interactions were quantitated by real-time PCR 1010 
(qPCR) using primers designed within restriction fragments (Supplementary Table 31). qPCR was 1011 
performed on a RotorGene 6000 using MyTaq HS DNA polymerase (Bioline) with the addition of 5 1012 
mM of Syto9, annealing temperature of 66
o
C and extension of 30 sec. 3C analyses were performed 1013 
in three independent 3C libraries from each cell line with each experiment quantified in duplicate. 1014 
BAC clones covering each region were used to create artificial libraries of ligation products in order 1015 
to normalize for PCR efficiency. Data were normalized to the signal from the BAC clone library and, 1016 
between cell lines, by reference to a region within GAPDH. All qPCR products were electrophoresed 1017 
on 2% agarose gels, gel purified and sequenced to verify the 3C product.  1018 
 1019 
Plasmid Construction and Reporter Assays 1020 
Promoter-driven luciferase reporter constructs were generated by insertion of PCR amplified 1021 
fragments or synthesised gBlocks (Integrated DNA Technologies) containing the KLHDC7A, PIDD1 or 1022 
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CITED4 promoters into the KpnI/HindIII sites of pGL3-Basic. For the 1p34 locus, a 1169 bp putative 1023 
regulatory element (PRE1) or 951 bp PRE2 were synthesised as gBlocks and cloned into the 1024 
BamHI/SalI sites of the CITED4-promoter construct. The minor alleles of SNPs were introduced into 1025 
promoter or PRE sequences by overlap extension PCR or gBlocks. Sequencing of all constructs 1026 
confirmed variant incorporation (AGRF). MCF7 or Bre-80 cells were transfected with equimolar 1027 
amounts of luciferase reporter plasmids and 50 ng of pRLTK transfection control plasmid with 1028 
Lipofectamine 2000. The total amount of transfected DNA was kept constant at 600 ng for each 1029 
construct by the addition of pUC19 as a carrier plasmid. Luciferase activity was measured 24 hr 1030 
posttransfection by the Dual-Glo Luciferase Assay System. To correct for any differences in 1031 
transfection efficiency or cell lysate preparation, Firefly luciferase activity was normalized to Renilla 1032 
luciferase, and the activity of each construct was measured relative to the reference promoter 1033 
constructs, which had a defined activity of 1. Statistical significance was tested by log transforming 1034 
the data and performing 2-way ANOVA, followed by Dunnetts multiple comparisons test in 1035 
GraphPad Prism.  1036 
 1037 
Global Genomic Enrichment Analyses 1038 
We performed stratified LD score regression analyses
17
 for overall breast cancer as well as stratified 1039 
by ER status using the summary statistics based on the meta-analyses of the OncoArray, GWAS and 1040 
iCOGS datasets. We restricted analysis to all SNPs present on the HapMap version 3 dataset that had 1041 
a MAF > 1% and an imputation quality score R
2
>0.3 in the OncoArray data. LD scores were calculated 1042 
using the 1000 Genomes Project Phase 3 EUR reference panel. 1043 
We first created a full baseline model as previously described that included 24 non-cell type 1044 
specific publicly available annotations as well as 24 additional annotations that included a 500-bp 1045 
window around each of the 24 main annotations
17
. Additionally, we also included 100-bp windows 1046 
around ChIP-seq peaks as well as one annotation containing all SNPs leading to a total of 53 1047 
overlapping annotations. 1048 
We subsequently performed analyses using cell-type specific annotations for four histone marks 1049 
H3K4me1, H3K4me3, H3K9ac and H3K27ac across 27-81 cell types depending on histone mark
17
. 1050 
Each cell-type-specific annotation corresponded to a histone mark in a single cell type, and there 1051 
were 220 such annotations in total. We augmented the baseline model by adding these annotations 1052 
individually, creating 220 separate models, each with 54 annotations (53+1). This procedure controls 1053 
for the overlap with the 53 functional categories in the full baseline model but not with the 219 1054 
other cell type specific annotations. 1055 
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We further tested the differences in functional enrichment between ER-positive and ER-negative 1056 
subsets through a Wald test, using the regression coefficients and standard errors for the two 1057 
subsets based on the models described above.  1058 
 1059 
Contribution of Identified Variants to the Familial Relative Risk of Breast Cancer 1060 
We estimated the proportion of the familial risk of breast cancer due to the identified variants, 1061 
under a log-additive model, using the formula: 1062 	? ݌௜ሺ	? െ ݌௜௜ ሻሺߚ௜ଶ െ ߬௜ଶሻ ሺߣሻ	? ), where ݌௜ is the MAF for variant i, ߚ௜is the log(OR) estimate for 1063 
variant i, ʏi is the standard error of ɴi and ʄ=2 is the assumed overall familial relative risk. 1064 
 1065 
To compute the corresponding estimate for the FRR due to all variants, we wish to estimate 1066 ݄௙ଶ ൌ 	? 	?݌௜ሺ	? െ ݌௜௜ ሻߚ௜ଶwhere the sum is now over the all variants and ɴi is the true relative risk 1067 
conferred by variant i, assuming a log-additive model. We refer to ݄௙ଶ as the frailty scale heritability. 1068 
We first obtained the estimated observed heritability based on the full set of summary estimates 1069 
using LD Score Regression
17
 and then converted this to an estimate on the frailty scale using the 1070 ݄௙ଶ ൌ ݄௢௕௦ଶ ܲሺ	? െ ܲሻ൘ , where P is the proportion of samples in the population that are cases.  1071 
 1072 
Pathway Analyses 1073 
The pathway gene set database (http://download.baderlab.org/EM_Genesets, file 1074 
Human_GOBP_AllPathways_no_GO_iea_April_01_2017_symbol.gmt)
13
 from the Bader lab dated 1075 
April 1, 2017 was used in all analyses. This database contains pathways from Reactome
61
, NCI 1076 
Pathway Interaction Database
62
, GO (Gene Ontology) biological process
63
, HumanCyc
64
, MSigdb
65
, 1077 
NetPath
66
 and Panther
67
. For GO, terms inferred from electronic annotation were excluded from our 1078 
analyses. The same pathway may be defined in two or more databases with potentially different sets 1079 
of genes. All versions of such duplicate pathways were included. To provide more biologically 1080 
meaningful results and reduce false positives, only pathways that contained between 10 and 200 1081 
genes were used. Pathway size was determined by the total number of genes in the pathway that 1082 
could also be mapped to the genes included in the GWAS dataset (actual pathway size may be 1083 
larger). 1084 
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 1085 
SNPs were assigned to genes using the INQUISIT target prediction method described above for all 1086 
SNPs with P-value < 5x10
-2
 (~1.25 million associations). This cutoff was chosen based on a threshold 1087 
analysis that showed that 19 of the 20 pathway themes found using all SNP associations (~16 million) 1088 
and a simple distance-based SNP-to-gene mapping method could be recovered using this smaller 1089 
subset of associations. More stringent cutoffs resulted in fewer themes being covered (e.g. three 1090 
themes found using SNPs with p-value < 5x10
-6
 or ~33K SNP associations). Gene significance was 1091 
calculated by assigning the statistic of the most significant SNP among all SNPs assigned to a 1092 
gene
68,69
. Since histone genes contained a high number of mapped SNPs, we selected representative 1093 
SNP associations to avoid pathway enrichments based solely on the increased number of SNPs at 1094 
these loci (i.e. chr6:27657944 for HIST1, chr1:149219841, for HIST2, chr1: 228517406 for HIST3, 1095 
chr12: 14871747 for HIST4). 1096 
 1097 
The gene set enrichment analysis (GSEA) algorithm as implemented in the GenGen package
69
 was 1098 
used to perform pathway analysis. Wang et al.
70
  modified the original GSEA algorithm to work with 1099 
GWAS datasets, using SNP significance and SNP-to-gene mapping instead of gene expression data. 1100 
Briefly, the algorithm calculates an enrichment score (ES) for each pathway based on a weighted 1101 
Kolmogorov-Smirnov statistic (refer to 
70
 for more details). Pathways that have most of their genes 1102 
at the top of the ranked list of genes obtain higher ES values. Note that only the largest positive ES 1103 
was considered as opposed to largest absolute ES (i.e. largest deviation from zero). This modification 1104 
(recommended by the GenGen authors for GWAS analysis) was performed to include only pathways 1105 
that are significantly affected between cases and controls and ignore those with significant negative 1106 
ES values (this may happen if a pathway is significantly less altered than expected by chance). Only 1107 
pathways containing greater than 10 genes with at least one of these genes with P-value < 5x10
-8
 1108 
were retained as higher confidence for subsequent analysis. These pathways, together with the 1109 
genes reaching the significance threshold, are listed in Supplementary Table 21. 1110 
 1111 
The pathway analysis assigns an enrichment score (ES) value for each pathway.  These values were 1112 
normalized and p-values for each pathway were obtained by comparing them to null distributions 1113 
for OncoArray and iCOGS data sets separately.  The null distributions were computed by permuting 1114 
case/control labels 1,000 times (keeping the number of cases and controls the same in each 1115 
iteration) and recomputing all enrichment statistics.  FDR values were computed using the statistics 1116 
from the null distributions and all pathways with FDR < 0.05 in either OncoArray or iCOGS 1117 
distributions were considered further. Pathway findings were further considered if they contained 1118 
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more than one significant gene and if they could be confirmed to be involved in breast cancer as 1119 
reported in at least one of five published large-scale breast cancer GWAS
71-75
 or reported elsewhere 1120 
in the literature. Further, themes that were weakly associated with breast cancer (based on a 1121 
literature search) were only included if they had a FDR < 0.05 and at least four novel genes (i.e. was 1122 
not found among the genes from mapped themes containing pathways known to be involved in 1123 
breast cancer) (Extended Data Fig. 2). Pathways related to sensory perception of smell were 1124 
removed as there is no literature evidence for their involvement in breast cancer and because they 1125 
contain genes close to each other on chromosome 6 which are frequently correlated.  1126 
 1127 
An enrichment map was created using the Enrichment Map (EM) v 2.1.0 app
13
 in Cytoscape v 3.3
76
. 1128 
Pathways nodes were laid out using a force directed layout and nodes with gene set overlap of over 1129 
0.55 were connected by edges. Related pathway nodes were manually clustered and labelled as 1130 
themes. 1131 
  1132 
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Extended Data Table 1: INQUISIT, DEPICT, and nearest gene as predictors of driver status. 1359 
Scores converted into levels for analysis. For INQUISIT: level 1 (coding score of 2 OR promoter 1360 
score of 3 or 4 OR distal score > 4), level 2 (coding score of 1 OR promoter of 1 or 2 OR distal 1361 
score of 1, 2, 3, or 4), level 3 (coding/promoter/distal scores > 0 but < 1), and level 4 (not 1362 
predicted to be a target gene by INQUISIT). For DEPICT: level 1 (DEPICT predicted target gene at 1363 
P ч 0.05), level 2 (DEPICT predicted target gene but with P > 0.05), level 3 (not predicted to be a 1364 
target gene by DEPICT). 1365 
 1366 
Extended Data Figure 1: Global mapping of biofeatures across novel loci associated with 1367 
overall breast cancer risk. The overlaps between potential genomic predictors in relevant breast 1368 
cell lines and candidate causal risk variants (CRVs) within each locus. On the x-axis, each column 1369 
represents a CRV (see Online Methods). The most significant SNPs are identified in each region. 1370 
On the y-axis, biofeatures are grouped into five functional categories: genomic structure (red), 1371 
enhancer marks (dark green), histone marks (blue), open chromatin marks (dark blue) and 1372 
transcription factor binding sites (dark violet). Colored elements indicate SNPs for which the 1373 
feature is present. For data sources, see Online Methods (In-Silico Analysis of CRVs).  1374 
 1375 
Extended Data Figure 2: Pathway enrichment map for susceptibility loci based on summary 1376 
association statistics. Each circle (node) represents a pathway (gene set), coloured by 1377 
enrichment score (ES) where redder nodes indicate lower FDRs. Larger nodes indicate pathways 1378 
with more genes. Green lines connect pathways with overlapping genes (minimum overlap 1379 
0.55). Pathways are grouped by similarity and organized into major themes (large labelled 1380 
circles).  1381 
 1382 
Extended Data Figure 3. Heatmap showing patterns of cell type-specific enrichments for 1383 
breast tissue across three histone marks (H3K4me1, H3K4me3 and H3K9ac) for breast cancer 1384 
overall, ER-positive breast cancer and ER-negative breast cancer as well as 16 other traits. 1385 
 1386 
Extended Data Figure 4: Heatmap showing patterns of cell type-specific enrichments for 1387 
histone mark H3K27ac in breast cancer overall, ER+ and ER- breast cancer as well as 16 1388 
other traits.  1389 
 1390 
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Extended Data Figure 5: Heatmap showing patterns of cell type-specific enrichments for 1391 
histone mark H3K4me1 in breast cancer overall, ER+ and ER- breast cancer as well as 16 1392 
other traits.  1393 
 1394 
Extended Data Figure 6: Heatmap showing patterns of cell type-specific enrichments for 1395 
histone mark H3K4me3 in breast cancer overall, ER+ and ER- breast cancer as well as 16 1396 
other traits. 1397 
 1398 
Extended Data Figure 7: Heatmap showing patterns of cell type-specific enrichments for 1399 
histone mark H3K9ac in breast cancer overall, ER-positive and ER-negative breast cancer 1400 
as well as 16 other traits. 1401 
 1402 
Extended Data Figure 8: Functional assessment of regulatory variants at 1p36, 11p15 and 1p34 1403 
risk loci. a, The KLHDC7A or b, PIDD1 promoter regions containing the reference (prom-Ref) or 1404 
risk alleles (prom-Hap), were cloned upstream of the pGL3 luciferase reporter gene. MCF7 or 1405 
Bre-80 cells were transfected with constructs and assayed for luciferase activity after 24 h. Error 1406 
bars denote 95% CI (n=3). P-values were determined by two-way ANOVA followed by Dunnetts 1407 
multiple comparisons test (*P<0.05, **P<0.01, ***P<0.001). c, 3C assays. A physical map of the 1408 
region interrogated by 3C is shown first. Grey boxes depict the putative regulatory elements 1409 
(PREs), blue vertical lines indicate the risk-associated SNPs and black dotted line represents 1410 
chromatin looping. The graphs represent three independent 3C interaction profiles. 3C libraries 1411 
were generated with EcoRI, grey vertical boxes indicate the interacting restriction fragment 1412 
(containing PRE1 and PRE2). Error bars denote SD. d, PRE1 or PRE2 containing the reference 1413 
(PRE-ref) or risk (PRE-Hap) haplotypes were cloned downstream of a CITED4 promoter-driven 1414 
luciferase construct (CITED4 prom). MCF7 or Bre-80 cells were transfected with constructs and 1415 
assayed for luciferase activity after 24 h. Error bars denote 95% CI (n=3). P-values were 1416 
determined by two-way ANOVA followed by Dunnetts multiple comparisons test (**P<0.01, 1417 
***P<0.001). 1418 
 1419 
Extended Data Figure 9: Functional assessment of regulatory variants at the 7q22 risk locus. a-1420 
e, 3C assays. A physical map of the region interrogated by 3C is shown first. Grey horizontal 1421 
boxes depict the putative regulatory elements (PREs), blue vertical lines indicate the risk-1422 
associated SNPs and black dotted line represents chromatin looping. The graphs represent three 1423 
independent 3C interaction profiles between the a, CUX1, b, d, PRKRIP1 or c, e, RASA4 promoter 1424 
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regions and PREs. 3C libraries were generated with EcoRI, grey vertical boxes indicate the 1425 
interacting restriction fragment (containing PRE1 and/or PRE2). Error bars denote SD. f, g, Allele-1426 
specific 3C. 3C followed by Sanger sequencing for the f, PRKRIP1-PRE2 or g, RASA4-PRE1 or -1427 
PRE2 in heterozygous MDA-MB-231 breast cancer cells. 1428 
 1429 
 1430 


